As 2026 begins, the European project SPEEDCELL reaffirms its commitment to the values that define its mission: optimising the development and manufacturing processes based on cell lines, a key modality in the production of vaccines and other biologics.
Funded by the EU4Health programme and coordinated by HIPRA, SPEEDCELL aims to accelerate the development and production of vaccines and other biologics in response to future health emergencies. A project that directly supports the “100 Days Mission”, an initiative of the European Union with a main goal: enabling biologic products to be developed and manufactured within just 100 days from the detection of a global health threat.
In the new year, the European project continues to move forward with the same clear purpose: protecting lives and reinforcing global health security through smarter and faster development and manufacturing systems for biologics.
